<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174105</url>
  </required_header>
  <id_info>
    <org_study_id>AT845-01</org_study_id>
    <nct_id>NCT04174105</nct_id>
  </id_info>
  <brief_title>Gene Transfer Study in Patients With Late Onset Pompe Disease</brief_title>
  <acronym>FORTIS</acronym>
  <official_title>A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Audentes Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Audentes Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2 open-label, ascending dose, multicenter clinical study to evaluate the&#xD;
      safety and efficacy of AT845 in adult (aged ≥ 18 years) subjects, ambulatory or&#xD;
      nonambulatory, with Late Onset Pompe Disease (LOPD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study (FORTIS) will evaluate the safety and efficacy of an investigational gene&#xD;
      replacement therapy, AT845, in adult subjects with LOPD. Subjects will receive a single dose&#xD;
      of AT845 delivered via intravenous (IV) infusion.&#xD;
&#xD;
      Up to 2 nominal dose levels of AT845 are planned to be evaluated in FORTIS. A single AT845&#xD;
      administration via IV infusion is planned for each subject. The initial dosing cohort will&#xD;
      receive a single dose at 3x10^13 vg/kg of AT845. The second dose cohort will receive a single&#xD;
      dose at 6x10^13 vg/kg of AT845.&#xD;
&#xD;
      The core observation period will be completed by Week 48 for each subject. Subjects will be&#xD;
      followed for a total of 5 years after administration of AT845.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Up to 2 nominal dose levels of AT845 are planned to be evaluated in FORTIS. A single AT845 administration via intravenous (IV) infusion is planned for each subject.The initial dosing cohort will receive a single dose at 3x10^13 vg/kg of AT845. The second dose cohort will receive a single dose at 6x10^13 vg/kg of AT845.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability over time</measure>
    <time_frame>Change from baseline through Week 48</time_frame>
    <description>Frequency of adverse events, serious adverse events, and changes from baseline in relevant clinical laboratory tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GAA protein expression</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in GAA protein expression in muscle biopsies at week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GAA enzymatic activity</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in GAA enzymatic activity in muscle biopsies at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vector Copy Number and mRNA Transcripts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline in muscle biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thigh Fat Fraction</measure>
    <time_frame>Baseline and Month 18</time_frame>
    <description>Change from baseline in thigh fat fraction by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test (for ambulatory patients)</measure>
    <time_frame>Baseline, Week 24 and Week 48</time_frame>
    <description>Change from baseline in the distance walked in the six minute walk test (6MWT), which is a standardized assessment of how far an individual can walk on a hard, flat surface in a period of 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline, Week 24 and Week 48</time_frame>
    <description>Change from baseline in percentage of predicted FVC measured by pulmonary function testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Inspiratory Pressure (MIP)</measure>
    <time_frame>Baseline, Week 24 and Week 48</time_frame>
    <description>Change from baseline in MIP measured by pulmonary function testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Expiratory Pressure (MEP)</measure>
    <time_frame>Baseline, Week 24 and Week 48</time_frame>
    <description>Change from baseline in MEP measured by pulmonary function testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Questionnaire</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in health profiles and overall health status as assessed by the EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rasch-built Pompe-specific Activity (R-PAct) scale</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in the R-PAct scale, which was developed to measure Pompe patients' ability carry out daily life activities and social participation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Change from baseline in scores of PROMIS short forms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Pompe Disease (Late-onset)</condition>
  <arm_group>
    <arm_group_label>Initial Dose Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3x10^13 vg/kg of AT845 administered via intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Dose Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6x10^13 vg/kg of AT845 administered via intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AT845</intervention_name>
    <description>AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter</description>
    <arm_group_label>Initial Dose Cohort</arm_group_label>
    <arm_group_label>Second Dose Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subject is aged ≥ 18 years (ambulatory or nonambulatory).&#xD;
&#xD;
          -  Subject has a documented clinical diagnosis of Pompe disease by genetic testing.&#xD;
&#xD;
          -  Subject has received enzyme replacement therapy (ERT) with rhGAA for the previous ≥ 2&#xD;
             years.&#xD;
&#xD;
          -  Subject has been on a stable standard dose (at least 20 mg/kg every 2 weeks) of ERT&#xD;
             with rhGAA for at least the previous 6 months.&#xD;
&#xD;
          -  Subject has upright FVC ≥ 30% of predicted normal value.&#xD;
&#xD;
          -  Subject or legally authorized representative(s) (LAR) (if applicable) provides written&#xD;
             informed consent.&#xD;
&#xD;
          -  Subject must agree to use appropriate contraception following consent through 6 months&#xD;
             post AT845 administration.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Subject is currently participating in an interventional study or has received gene or&#xD;
             cell therapy.&#xD;
&#xD;
          -  Subject tests positive for AAV8 neutralizing antibodies with titers above protocol&#xD;
             specified threshold.&#xD;
&#xD;
          -  Subject has received immune-modulating agents within 90 days before dosing (use of&#xD;
             inhaled corticosteroids is allowed).&#xD;
&#xD;
          -  Subject tests positive for GAA total antibodies with titers above protocol specified&#xD;
             threshold.&#xD;
&#xD;
          -  Subject has a high risk for a severe allergic reaction to rhGAA (ie, previous moderate&#xD;
             to severe anaphylactic reaction to alglucosidase alfa or and/or a history of sustained&#xD;
             high immunoglobulin G [IgG] antibody titers to alglucosidase alfa that in the opinion&#xD;
             of the Investigator suggests a high risk for an allergic reaction to ERT).&#xD;
&#xD;
          -  Subject has an active viral infection based on clinical observation.&#xD;
&#xD;
          -  Subject has a history of, or currently has, a clinically important cardiac condition,&#xD;
             such as an echocardiogram (ECHO) with ejection fraction below 40%, or has symptoms or&#xD;
             signs of cardiomyopathy that in the opinion of the Investigator precludes enrollment.&#xD;
&#xD;
          -  Subject has a clinically significant underlying liver disease.&#xD;
&#xD;
          -  Subject has a contraindication to study drug or ingredients or to corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Smith, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Audentes Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Audentes Patient Advocacy</last_name>
    <phone>+1-833-450-2759</phone>
    <email>trials@audentestx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Irvine, Department of Neurology</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Scott</last_name>
      <phone>714-456-5956</phone>
      <email>stemcell@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Tahseen Mozaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-725-4341</phone>
      <email>NeuromuscularResearch@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John Day, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>To be announced</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>To be announced</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>To be announced</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah, Division of Medical Genetics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenzie Fait</last_name>
      <phone>801-585-7160</phone>
      <email>kenzie.fait@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Nicola Longo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximillians University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Wenninger</last_name>
      <email>Stephan.Wenninger@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Wenninger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals Foundation Trust Clinical Research Facility</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Fitzsimmons</last_name>
      <phone>0191 241 8663</phone>
      <email>Sam.fitzsimmons@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jordi Diaz-Manera, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LOPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

